Division of Cardiology, Bristol Heart Institute, Bristol, UK.
Division of Cardiology, Bristol Heart Institute, Bristol, UK
BMJ Case Rep. 2021 Sep 3;14(9):e243604. doi: 10.1136/bcr-2021-243604.
We herein report the case of a 53-year-old man who was historically diagnosed with hypertrophic cardiomyopathy (HCM) and was lost to follow-up, before presenting with end-stage heart failure. This was initially suspected as dilated cardiomyopathy and then 'burnt-out phase' of HCM but subsequently the underlying diagnosis was Fabry disease. Fabry disease is an uncommon lysosomal-storage disease due to reduced or absent activity of the alpha-galactosidase A enzyme. Cardiac involvement most frequently comprises left ventricular hypertrophy. Early treatment of the underlying condition with enzyme replacement therapy may prevent the progression to end-stage heart failure. Fabry disease should be considered in all patients presenting with a clinical phenotype of HCM and a historical diagnosis should be re-evaluated in light of new diagnostic tools. Untreated Fabry can progress to a 'burnt out' phase, whereby initial hypertrophy undergoes eccentric remodelling to a dilated, severely impaired left ventricle.
我们在此报告一例 53 岁男性病例,该患者既往被诊断为肥厚型心肌病(HCM),失访后出现终末期心力衰竭。最初怀疑为扩张型心肌病,随后为 HCM 的“耗竭期”,但随后的潜在诊断为法布瑞病。法布瑞病是一种罕见的溶酶体贮积病,由于α-半乳糖苷酶 A 酶的活性降低或缺失。心脏受累最常见的表现为左心室肥厚。早期用酶替代疗法治疗潜在疾病可能阻止疾病进展为终末期心力衰竭。对于所有表现出 HCM 临床表型的患者都应考虑法布瑞病,并且应根据新的诊断工具重新评估既往诊断。未经治疗的法布瑞病可能进展为“耗竭期”,最初的肥厚会发生偏心重塑,导致扩张性、严重受损的左心室。